Cargando…

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)

BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and reduced cardiovascular morbidity and mortality...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sudano, Isabella, Mach, Francois, Moccetti, Tiziano, Burkard, Thilo, Fahe, Christian, Delabays, Alain, Rickli, Hans, Keller, Pierre-Frédéric, Dopheide, Jörn, Bodenmann, Sereina, Fiolka, Tom, Ehret, Georg, Spirk, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335009/ https://www.ncbi.nlm.nih.gov/pubmed/35911507 http://dx.doi.org/10.3389/fcvm.2022.953040

Ejemplares similares

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
por: Langslet, Gisle, et al.
Publicado: (2020)

Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study
por: Pérez de Isla, Leopoldo, et al.
Publicado: (2023)

Sitosterolemia Exhibiting Severe Hypercholesterolemia with Tendon Xanthomas Due to Compound Heterozygous ABCG5 Gene Mutations Treated with Ezetimibe and Alirocumab
por: Tanaka, Hiroki, et al.
Publicado: (2020)

Familial Hypercholesterolemia and the Atherosclerotic Disease
por: Kim, Yoo Ri, et al.
Publicado: (2013)

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
por: Matta, Anthony, et al.
Publicado: (2023)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease
por: Weintraub, Spencer F., et al.
Publicado: (2022)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
por: Kastelein, John J. P., et al.
Publicado: (2014)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
por: Ge, Xiaoyue, et al.
Publicado: (2021)

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Naito, Ryo, et al.
Publicado: (2022)

Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
por: Ershova, Alexandra I., et al.
Publicado: (2016)

Optimizing Treatment of Familial Hypercholesterolemia in Children and Adolescents
por: Luirink, Ilse K., et al.
Publicado: (2015)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
por: Nam, Chang-Wook, et al.
Publicado: (2019)

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
por: Dardano, Angela, et al.
Publicado: (2021)

Impact of the severe familial hypercholesterolemia status on atherosclerotic risks
por: Tada, Hayato, et al.
Publicado: (2023)

Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children
por: Sonnett, Travis, et al.
Publicado: (2010)

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
por: Agarwala, Anandita, et al.
Publicado: (2021)

Awareness and knowledge of heterozygous familial hypercholesterolemia among Serbian pediatricians
por: Bjelakovic, Ljiljana, et al.
Publicado: (2023)

Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
por: Bruckert, Eric, et al.
Publicado: (2022)

Optimal management of familial hypercholesterolemia: treatment and management strategies
por: Nemati, Mohammad Hassan, et al.
Publicado: (2010)

Optimal Use of Plant Stanol Ester in the Management of Hypercholesterolemia
por: Rosin, Susanna, et al.
Publicado: (2015)

Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor
por: Jarauta, Estíbaliz, et al.
Publicado: (2020)

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
por: Mallya, Usha G., et al.
Publicado: (2017)

Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia
por: Peterson, Amy L., et al.
Publicado: (2021)

Genetically confirmed familial hypercholesterolemia in outpatients with hypercholesterolemia
por: Wang, Xu, et al.
Publicado: (2018)

Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis: Identification Methods, Patient Activation, and Cascade Testing for Familial Hypercholesterolemia
por: Campbell-Salome, Gemme, et al.
Publicado: (2021)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
por: Stroes, Erik, et al.
Publicado: (2016)

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study
por: Barrios, Vivencio, et al.
Publicado: (2022)

Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease
por: Trinder, Mark, et al.
Publicado: (2020)

The Assessment of Carotid Atherosclerotic Plaque among Young Patients with Familial Hypercholesterolemia
por: Shibayama, Junichi, et al.
Publicado: (2022)

Correlates of Coronary Artery Calcification Prevalence and Severity in Patients With Heterozygous Familial Hypercholesterolemia
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2020)

Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins
por: Marco-Benedí, Victoria, et al.
Publicado: (2021)

How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
por: Kataoka, Yu, et al.
Publicado: (2022)

Familial Hypercholesterolemia
por: Baruah, Dibya Kumar
Publicado: (2021)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Anti-atherosclerotic effect of Cynodon dactylon extract on experimentally induced hypercholesterolemia in rats
por: Pashaie, Belal, et al.
Publicado: (2017)

Familial hypercholesterolemia with early coronary atherosclerotic heart disease: A case report
por: Luo, Yanhong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ktj1ovf1hsjt6kapjlr7d6un7v